Zai Lab Reports Q3 2026 Financial Results and Outlines Key 2027 Pipeline Catalysts

Executive Summary

On November 5, 2026, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) filed a Form 8-K under Item 2.02 reporting financial results for the third quarter ended September 30, 2026, alongside corporate updates and clinical pipeline milestones.

Financial Highlights

• Revenues: Total revenue was $108.2 million for Q3 2026, compared to $116.1 million in Q3 2025. Net product revenue reached $107.6 million, marking a 2% sequential increase over Q2 2026, supported by NUZYRA growth and the June 2026 launch of KarXT, partially offset by OPTUNE decline.
• Operating Expenses:
  • Research & Development (R&D): $49.8 million, compared to $47.9 million in Q3 2025.
  • Selling, General & Administrative (SG&A): $70.1 million, flat compared to Q3 2025.
• Operating Loss & Net Loss:
  • Operating loss stood at $63.0 million (Non-GAAP adjusted operating loss of $47.6 million).
  • Net loss was $46.1 million ($0.04 per ordinary share / $0.41 per ADS), wider than $36.0 million ($0.03 per ordinary share / $0.33 per ADS) in Q3 2025, impacted by $13.6 million in inventory write-downs.
• Cash & Liquidity: Cash, cash equivalents, restricted cash, and short-term investments totaled $659.7 million as of September 30, 2026.

Subsequent Financing Event

• On October 27, 2026, Zai Lab closed a private placement of 11,340,000 ADSs at $22.04 per ADS, generating gross proceeds of $250.0 million and net proceeds of approximately $241.2 million to fund clinical pipeline development and corporate purposes.

Key Clinical & Regulatory Catalysts

• Zocilurtatug Pelitecan (zoci, DLL3-targeting ADC):
  • Phase 3 global trial in 1L ES-SCLC initiation anticipated by year-end 2026 following positive Phase 1 combination data with atezolizumab (81.8% confirmed ORR).
  • Ongoing Phase 3 DLLEVATE study in 2L+ SCLC with potential interim analysis in 2H 2027.
  • 2L+ epNECs expansion cohort fully enrolled; topline data in 1H 2027 to support potential U.S. BLA accelerated approval submission.
• ZL-1503 (IL-13/IL-31Rα):
  • First-in-human healthy volunteer SAD data scheduled for ACAAI Annual Meeting in November 2026.
  • Initial MAD patient data in atopic dermatitis expected in 1H 2027.